Literature DB >> 28888813

Gender-specific Differences in Recurrence of Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.

Annemarie Uhlig1, Arne Strauss2, Ali Seif Amir Hosseini3, Joachim Lotz3, Lutz Trojan2, Marianne Schmid2, Johannes Uhlig4.   

Abstract

CONTEXT: The incidence of urothelial carcinoma of the bladder (UCB) is lower in women; however, women tend to present with more advanced disease. To date, there is no quantitative synthesis of studies reporting gender-specific outcomes in non-muscle-invasive UCB.
OBJECTIVE: To conduct a meta-analysis evaluating gender-specific differences in recurrence of non-muscle-invasive urinary bladder cancer (NMIBC). EVIDENCE ACQUISITION: An unrestricted systematic literature search of the MEDLINE, EMBASE, and Cochrane libraries was conducted. Studies evaluating the impact of gender on disease recurrence after local treatment of NMIBC using multivariable Cox proportional hazard models were included. Random effect meta-analysis, subgroup analyses, meta-influence, and cumulative meta-analyses were conducted. Publication bias was assessed via a funnel plot and Eggeŕs test. EVIDENCE SYNTHESIS: Of 609 studies screened, 27 comprising 23 754 patients were included. Random effect meta-analyses indicated women at increased risk for UCB recurrence compared with men (hazard ratio [HR]=1.11, 95% confidence interval [CI]: 1.01-1.23, p=0.03). Subgroup analyses yielded estimates between HR=0.99 and HR=1.68. Gender-specific differences in UCB recurrence were most pronounced in studies administering exclusively bacillus Calmette-Guerin (BCG; HR=1.64, 95% CI: 1.13-2.39, p=0.01), especially in a long-term treatment regimen (HR=1.68, 95% CI: 1.32-2.15, p<0.001). Sensitivity analyses confirmed female patients at increased risk for UCB recurrence.
CONCLUSIONS: Women are at increased risk for disease recurrence after local treatment of NMIBC compared with male patients. Reduced effectiveness of BCG treatment might underlie this observation. Gender-specific differences were evident across various subgroups and proved robust upon sensitivity analyses. PATIENT
SUMMARY: In this report, we combined several studies on gender-specific differences in relapse of superficial bladder cancer. Women were more likely to experience cancer relapse than men.
Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Gender differences; Local recurrence; Meta-analysis; Transurethral resection of bladder tumor

Mesh:

Substances:

Year:  2017        PMID: 28888813     DOI: 10.1016/j.euf.2017.08.007

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN: 2405-4569


  12 in total

Review 1.  [Gender-associated differences in bladder cancer].

Authors:  Georgios Gakis; Dorothea Weckermann
Journal:  Urologie       Date:  2022-08-18

2.  IC-2 Suppresses Proliferation and Induces Apoptosis of Bladder Cancer Cells via the Wnt/β-Catenin Pathway.

Authors:  Lingfeng Wu; Shunliang He; Yi He; Xueping Wang; Linfeng Lu
Journal:  Med Sci Monit       Date:  2018-11-11

3.  Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice.

Authors:  Kelly A Martin; Nicholas R Hum; Aimy Sebastian; Wei He; Salma Siddiqui; Paramita M Ghosh; Chong-Xian Pan; Ralph de Vere White; Gabriela G Loots
Journal:  Int J Mol Sci       Date:  2019-10-09       Impact factor: 5.923

4.  Impact of Androgen Suppression Therapy on the Risk and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis.

Authors:  Peng Xiang; Zhen Du; Yongxiu Hao; Di Guan; Dan Liu; Wei Yan; Mingdong Wang; Yutong Liu; Hao Ping
Journal:  Front Oncol       Date:  2021-12-14       Impact factor: 6.244

5.  Sex differences in the aging murine urinary bladder and influence on the tumor immune microenvironment of a carcinogen-induced model of bladder cancer.

Authors:  Ali Hamade; Deyang Li; Kathrin Tyryshkin; Minqi Xu; Gwenaelle Conseil; Priyanka Yolmo; Jake Hamilton; Stephen Chenard; D Robert Siemens; Madhuri Koti
Journal:  Biol Sex Differ       Date:  2022-05-03       Impact factor: 5.027

Review 6.  The impact of biological sex on diseases of the urinary tract.

Authors:  Léa Deltourbe; Livia Lacerda Mariano; Teri N Hreha; David A Hunstad; Molly A Ingersoll
Journal:  Mucosal Immunol       Date:  2022-07-22       Impact factor: 8.701

Review 7.  Sex Hormone Receptor Signaling in Bladder Cancer: A Potential Target for Enhancing the Efficacy of Conventional Non-Surgical Therapy.

Authors:  Hiroki Ide; Hiroshi Miyamoto
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

Review 8.  The Role of Estrogen Receptors in Urothelial Cancer.

Authors:  Takuro Goto; Hiroshi Miyamoto
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-16       Impact factor: 5.555

9.  Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin Immunotherapy.

Authors:  Matteo Ferro; Octavian Sabin Tătaru; Gennaro Musi; Giuseppe Lucarelli; Abdal Rahman Abu Farhan; Francesco Cantiello; Rocco Damiano; Rodolfo Hurle; Roberto Contieri; Gian Maria Busetto; Giuseppe Carrieri; Luigi Cormio; Francesco Del Giudice; Alessandro Sciarra; Sisto Perdonà; Marco Borghesi; Carlo Terrone; Evelina La Civita; Pierluigi Bove; Riccardo Autorino; Matteo Muto; Nicolae Crisan; Michele Marchioni; Luigi Schips; Francesco Soria; Daniela Terracciano; Rocco Papalia; Felice Crocetto; Biagio Barone; Giorgio Ivan Russo; Stefano Luzzago; Giuseppe Mario Ludovico; Mihai Dorin Vartolomei; Francesco Alessandro Mistretta; Vincenzo Mirone; Ottavio de Cobelli
Journal:  Diagnostics (Basel)       Date:  2022-02-25

10.  Sexual Dimorphism in Outcomes of Non-muscle-invasive Bladder Cancer: A Role of CD163+ Macrophages, B cells, and PD-L1 Immune Checkpoint.

Authors:  Stephen Chenard; Chelsea Jackson; Thiago Vidotto; Lina Chen; Céline Hardy; Tamara Jamaspishvilli; David Berman; D Robert Siemens; Madhuri Koti
Journal:  Eur Urol Open Sci       Date:  2021-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.